WASHINGTON (May 30, 2024) — The Association for Accessible Medicines, the leading trade association for generic and biosimilar manufacturers, today submitted comments to the U.S.
Families and physicians in certain parts of the country are finding it difficult to access commonly prescribed medicines, such as amoxicillin, this winter. The combination of widespread influenza, respiratory syncytial virus (RSV) and COVID infections – in what public health experts are calling a tripledemic
– has led to unforeseen demand for these low-cost generic treatments.
WASHINGTON, D.C. (December 20, 2022) – The Association for Accessible Medicines Interim President, David Gaugh, today released the following statement regarding the Consolidated Appropriations Act of 2023.
WASHINGTON, D.C. (August 16, 2021) — AAM and its member companies have worked extremely hard to enhance patient access to affordable treatments throughout the COVID-19 pandemic. This includes manufacturing dexamethasone, which is estimated to have saved more than 1 million lives worldwide, and producing under voluntary licensing agreements leading vaccines and other therapeutics for use by patients in developing countries.
This article first appeared in The Medicine Maker on March 22, 2021.
The U.S. generics and biosimilars industry, makers of 90% of our nation's prescription medicines, has a plan to "#SecureOurMeds." We already produce billions of doses of medicine right here in America, and our plan ensures continued patient access through COVID and beyond.
Learn more about our path forward at: https://www.secureourmeds.org/
This paper examines the challenges to market sustainability for generic and biosimilar medicines that have cleared the regulatory and patent hurdles to obtain FDA approval and launch into the U.S. market. It is the first in a series of AAM papers that will highlight challenges to the overall sustainability of the generics and biosimilars industry.
Association for Accessible Medicines Unveils Policy Agenda for
Biden Administration and 117th Congress
Outlines Policy Solutions to Support Long-Term Sustainability of Generic and Biosimilar Medicines
New Campaign Highlights Lifesaving Role Generic Drugs Have Played in Treatment of COVID-19
Report Series Examines Threats to Patient Access and Affordability
This article first appeared in Managed Healthcare Executive on February 1, 2021.
Generic and biosimilar medicines are a proven solution to lowering drug costs, and the use of these medicines saved more than $313 billion in 2019 alone. At a time of high economic insecurity, access to more-affordable generic and biosimilars means patients are more likely to fill and use a generic drug prescription.